{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:06:53Z","timestamp":1774559213981,"version":"3.50.1"},"reference-count":96,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T00:00:00Z","timestamp":1557619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Endometrial Cancer (EC) is an important cause of death in women worldwide. Despite early diagnosis and optimal treatment of localized disease, relapsed patients have few therapeutic options because after first line therapy, currently no standard of care exists. On the basis of endocrine positivity of most endometrioid ECs, Endocrine Therapy (ET) is a reasonable and widely accepted option. Better knowledge of molecular mechanisms involved in cancer highlighted the deregulated activity of Cyclin-Dependent Kinases (CDKs) in the cell cycle as a hallmark of carcinogenesis supporting the development of a new class of drugs: CDK inhibitors (CDKis). The aim of this review is to give an overview on CDKis preclinical, early clinical activity and future development in EC. Use of CDKis has a strong preclinical rationale but we have poor clinical data. Similar to breast cancer, most ongoing trials are investigating synergistic associations between CDKis and ET. These trials will probably help in defining the best clinical setting of CDKis in ECs, which are the best partner drugs, and how to manage CDKis toxicities with a focus on potential biomarkers of response.<\/jats:p>","DOI":"10.3390\/ijms20092353","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T05:35:39Z","timestamp":1557725739000},"page":"2353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer"],"prefix":"10.3390","volume":"20","author":[{"given":"Gaia","family":"Giannone","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Ghisoni","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Genta","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Scotto","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Mittica","sequence":"additional","affiliation":[{"name":"Units of Oncology, ASL Verbano Cusio Ossola (VCO), Via Fiume, 18, 28922 Verbania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy"},{"name":"Candiolo Cancer Institute-FPO-IRCCS, Strada Provinciale 142 km 3.95, 10060 Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"468","article-title":"Diagnosis and Management of Endometrial Cancer","volume":"93","author":"Braun","year":"2016","journal-title":"Am. Fam Physician"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.30094","article-title":"Endometrial cancer: Not your grandmother\u2019s cancer","volume":"122","author":"McAlpine","year":"2016","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.44","article-title":"The dose-effect relationship between \u2018unopposed\u2019 oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk","volume":"57","author":"Key","year":"1988","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1200\/JCO.2007.10.8597","article-title":"Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer","volume":"25","author":"Lu","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1245\/s10434-009-0736-6","article-title":"Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: Results from the ILIADE randomized study","volume":"16","author":"Signorelli","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"Powell","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2012.06.026","article-title":"Combined chemotherapy and radiation improves survival for node-positive endometrial cancer","volume":"127","author":"Lee","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2014.02.019","article-title":"Improving oncologic outcomes for women with endometrial cancer: Realigning our sights","volume":"133","author":"Dowdy","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kokka, F., Brockbank, E., Oram, D., Gallagher, C., and Bryant, A. (2010). Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst. Rev., CD007926.","DOI":"10.1002\/14651858.CD007926"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1200\/JCO.2015.61.7225","article-title":"Second-Line Therapy for Endometrial Cancer: The Need for Better Options","volume":"33","author":"Fleming","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"ref_15","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens","year":"2013","journal-title":"Facts Views Vis. Obgyn"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl Acad Sci USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2013.09.023","article-title":"Neoadjuvant treatment of endometrial cancer using anastrozole: A randomised pilot study","volume":"131","author":"Thangavelu","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0301-2115(02)00147-1","article-title":"Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: Endocrine and clinical effects","volume":"105","author":"Berstein","year":"2002","journal-title":"Eur J. Obstet Gynecol. Reprod Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","article-title":"Global burden of cancer attributable to high body-mass index in 2012: A population-based study","volume":"16","author":"Arnold","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jerzak, K.J., Duska, L., and MacKay, H.J. (2019). Endocrine therapy in endometrial cancer: An old dog with new tricks. Gynecol. Oncol.","DOI":"10.1016\/j.ygyno.2018.12.018"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","article-title":"Classification of endometrial carcinoma: More than two types","volume":"15","author":"Murali","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1373\/clinchem.2013.205740","article-title":"The emerging genomic landscape of endometrial cancer","volume":"60","author":"Bell","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","article-title":"Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis","volume":"22","author":"McConechy","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.06.008","article-title":"Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?","volume":"48","author":"Gargiulo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-0888-2_2","article-title":"Cell cycle regulation by checkpoints","volume":"1170","author":"Barnum","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fonc.2018.00303","article-title":"Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers","volume":"8","author":"Lin","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.biopha.2018.08.116","article-title":"An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers","volume":"107","author":"Chohan","year":"2018","journal-title":"Biomed. Pharmacother"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: Roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ncb1109-1275","article-title":"Cyclin-dependent kinases: A family portrait","volume":"11","author":"Malumbres","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(00)81519-6","article-title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1","volume":"98","author":"Harbour","year":"1999","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/sj.onc.1205690","article-title":"The cyclin H\/cdk7\/Mat1 kinase activity is regulated by CK2 phosphorylation of cyclin H","volume":"21","author":"Schneider","year":"2002","journal-title":"Oncogene"},{"key":"ref_41","unstructured":"Romano, D. (2018, January 23). Comparison of preclinical data across CDK 4-6 inhibitors. Proceedings of the ESMO Symposium on Signalling Pathways in Cancer 2018, Barcelona, Spain."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CCO.0b013e3282efb9da","article-title":"Flavopiridol in the treatment of chronic lymphocytic leukemia","volume":"19","author":"Christian","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs. ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"Finn","year":"2016","journal-title":"Nat.Rev.Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0092-8674(89)90507-2","article-title":"The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element","volume":"58","author":"DeCaprio","year":"1989","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006103831990","article-title":"Cyclin D1 in breast cancer","volume":"52","author":"Barnes","year":"1998","journal-title":"Breast Cancer Res.Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.4161\/cc.9.20.13454","article-title":"RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response","volume":"9","author":"Ertel","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc. Natl Acad Sci USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-Cell Dynamics Determines Response to CDK4\/6 Inhibition in Triple-Negative Breast Cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentiallyinhibits proliferation of luminal estrogen receptor-positive humanbreast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, N.A., Tomaso, E.D., Ayala, R., and Tong, L. (2014). Abstract 4756: In vivo efficacy of combined targeting of CDK 4\/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res., 74.","DOI":"10.1158\/1538-7445.AM2014-4756"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/ERC-10-0262","article-title":"Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer","volume":"18","author":"Thangavel","year":"2011","journal-title":"Endocr-Relat. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/17425255.2018.1514720","article-title":"Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer","volume":"14","author":"Maiello","year":"2018","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial","volume":"8","author":"Cutts","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: A CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: A review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-017-4612-y","article-title":"Potential biomarkers of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer","volume":"168","author":"Fang","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","article-title":"CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment","volume":"21","author":"DeMichele","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early Adaptation and Acquired Resistance to CDK4\/6 Inhibition in Estrogen Receptor-Positive Breast Cancer","volume":"76","author":"Palafox","year":"2016","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wander, S.A., Cohen, O., Johnson, G.N., Kim, D., Luo, F., Mao, P., Nayar, U., Helvie, K., Marini, L., and Freeman, S. (2018). Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.12016"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1054\/bjoc.1999.0980","article-title":"The role of p16-cyclin d\/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma","volume":"82","author":"Tsuda","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1007\/s13277-014-1703-9","article-title":"High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma","volume":"35","author":"Santala","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Tanaka, T., Terai, Y., Ashihara, K., Fujiwara, S., Tanaka, Y., Sasaki, H., Tsunetoh, S., and Ohmichi, M. (2017). The efficacy of the cyclin-dependent kinase 4\/6 inhibitor in endometrial cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177019"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/path.4896","article-title":"Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias","volume":"242","author":"Dosil","year":"2017","journal-title":"J. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Huang, K.T., Pavlides, S.C., Lecanda, J., Blank, S.V., Mittal, K.R., and Gold, L.I. (2012). Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: Pathogenic and therapeutic implications for endometrial cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046072"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1677\/erc.1.00993","article-title":"Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E","volume":"12","author":"Butt","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/endo.138.3.5002","article-title":"Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus","volume":"138","author":"Altucci","year":"1997","journal-title":"Endocrinology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s004320100255","article-title":"Expression of cell-cycle regulatory proteins in endometrial carcinomas: Correlations with hormone receptor status and clinicopathologic parameters","volume":"127","author":"Bamberger","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.198","article-title":"Dual CCNE1\/PIK3CA targeting is synergistic in CCNE1-amplified\/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo","volume":"115","author":"Cocco","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A Phase I Study of the Cyclin-Dependent Kinase 4\/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1200\/JCO.2016.34.15_suppl.2503","article-title":"Phase 1 study of sapacitabine and seliciclib in patients with advanced solid tumors","volume":"34","author":"Tolaney","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1078-0432.CCR-18-1967","article-title":"Arrested Developments: CDK4\/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment","volume":"25","author":"Teh","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","article-title":"To Cycle or Fight-CDK4\/6 Inhibitors at the Crossroads of Anticancer Immunity","volume":"25","author":"Ameratunga","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12957-015-0619-1","article-title":"Prognostic role of hormone receptors in endometrial cancer: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2015","journal-title":"World J. Surg Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"25521","DOI":"10.1038\/srep25521","article-title":"Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth","volume":"6","author":"Holst","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1517\/14712598.2015.995624","article-title":"Current opinion on bevacizumab on endometrial cancer treatment","volume":"15","author":"Bogliolo","year":"2015","journal-title":"Expert. Opin. Biol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/9\/2353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:51:18Z","timestamp":1760187078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/9\/2353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,12]]},"references-count":96,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20092353"],"URL":"https:\/\/doi.org\/10.3390\/ijms20092353","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,12]]}}}